WuXi XDC

WuXi XDC is a contract research, development and manufacturing organization (CRDMO) focused on antibody-drug conjugates (ADCs) and the broader bioconjugate market. Its stated proposition is to provide integrated, end-to-end services through a single-source platform, spanning discovery, development and cGMP manufacturing. The company’s service areas include bioconjugation discovery and process development, analytical development, formulation and drug-product development, GMP monoclonal-antibody intermediates and conjugation manufacturing, GMP formulation, filling and lyophilization, and payload and linker research, development and manufacturing. Its website also lists ready-made payloads and linkers and a WuXi XDC Singapore site. The company describes its laboratories and manufacturing facilities as proximately located and presents the integrated setup as a way to reduce development timelines and costs. WuXi XDC describes its work as serving the global ADC and broader bioconjugate market. Its website reports a workforce of more than 2,000 and characterizes its platform as open-access, with broad capabilities and technologies. The company is publicly listed under stock code 2268.HK. The supplied company materials do not specify its founding year, headquarters, founder, or ownership structure.

The supplied official materials describe WuXi XDC as a CRDMO focused on the global ADC and broader bioconjugate market, but do not provide a founding date or a detailed account of the company’s origins. They present its business model as an integrated, single-source offering covering discovery, development and cGMP manufacturing. The company’s listed service areas span bioconjugation discovery and process development, analytical development, formulation and drug-product development, GMP monoclonal-antibody intermediate and conjugation manufacturing, GMP formulation, filling and lyophilization, and payload and linker research, development and manufacturing. Ready-made payloads and linkers are also listed. WuXi XDC describes its laboratories and manufacturing facilities as proximately located, with the stated aim of reducing development timelines and costs. The company website identifies WuXi XDC as listed under stock code 2268.HK and names its executive directors and other board members. It also lists a WuXi XDC Singapore site and describes the company as serving a global market. The provided materials do not establish a founding year, headquarters, founder, ownership structure, or dated milestones, so these details are not asserted here.

• 2023

  Listed on the Hong Kong Stock Exchange under stock code 2268.HK.

• 2020

  WuXi XDC incorporated as a subsidiary of WuXi Biologics.

A single-source, open-access CRDMO partner for global ADC and bioconjugate discovery, development and manufacturing.

• Bioconjugation discovery and process development

  Discovery and process-development services for bioconjugation.

• Analytical development

  Analytical development services listed among the company’s offerings.

• Formulation and drug-product development

  Formulation and drug-product development services.

• GMP manufacturing

  Includes monoclonal-antibody intermediates and conjugation, as well as formulation, filling and lyophilization.

• Payload and linker services

  Research, development and manufacturing, with ready-made payloads and linkers also listed.

1. 1WuXi XDC Official Websitewuxixdc.com
2. 2About Us - WuXi XDCwuxixdc.com
3. 3Corporate Governance - WuXi XDCwuxixdc.com